Telo Genomics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Telo Genomics şirketinin toplam hissedar öz sermayesi CA$590.1K ve toplam borcu CA$0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CA$965.6K ve CA$375.6K dir.

Anahtar bilgiler

Borç/özkaynak oranı

CA$0

Borç

Faiz karşılama oranı	n/a
Nakit	CA$796.02k
Eşitlik	CA$590.06k
Toplam yükümlülükler	CA$375.59k
Toplam varlıklar	CA$965.64k

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: TDSG.F 'nin kısa vadeli varlıkları ( CA$919.0K ) kısa vadeli yükümlülüklerini ( CA$375.6K ) aşıyor.

Uzun Vadeli Yükümlülükler: TDSG.F un uzun vadeli yükümlülüğü bulunmamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: TDSG.F borçsuzdur.

Borcun Azaltılması: TDSG.F şu anda borcu yok ancak 5 yıl öncesine ait verimiz olmadığı için karşılaştırma yapamıyoruz.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: TDSG.F şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: TDSG.F un, serbest nakit akışı her yıl % 13.2 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Telo Genomics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Telo Genomics Corp. Presents New Performance Data for Its Smoldering Myeloma Prognostic Test

Telo Genomics Corp., Annual General Meeting, Nov 27, 2024

Telo Genomics Corp. Evaluates Minimal Residual Disease Biomarker Assay Technologies in Multiple Myeloma Patients as Part of the TELO-MRD Clinical Validation Study

Telo Genomics Corp. Announces Results of Development, Validation and Implementation of its Machine Learning and Artificial Intelligence Modules, Use in its TeloView Myeloma Diagnostic Tests

Telo Genomics Corp. announced that it expects to receive CAD 0.6 million in funding

Telo Genomics Corp. Announces Executive Changes

Telo Genomics Corp. Announces Clinical Launch of Non-Invasive Cancer Diagnostic, Teloviewsmm - an Important Commercial Milestone Achieved

Telo Genomics Presents Positive Results in Assessing Minimal Residual Disease in Multiple Myeloma Patients at the International Myeloma Society Annual Meeting

Telo Genomics Corp., Annual General Meeting, Nov 30, 2023

Telo Genomics Corp. announced that it has received CAD 2.833875 million in funding

Telo Genomics Corp. announced that it has received CAD 2.833875 million in funding

Telo Genomics Corp. Presents Positive Data in Newly Diagnosed Multiple Myeloma Drug Resistance Study at EHA 2023

Telo Genomics Corp. announced that it expects to receive CAD 2 million in funding

Telo Genomics' Multiple Myeloma Drug Resistance Study Results Selected for Presentation At the 2023 European Hematology Congress

Telo Genomics Corp Announces Chief Executive Officer Changes

Telo Genomics Corp. Launches A Minimal Residual Disease Clinical Trial in Multiple Myeloma

Telo Genomics Corp. Appoints Richard A. Bender to Establish and Chair its MM Clinical Advisory Board

Telo Genomics Corp., Annual General Meeting, Dec 01, 2022

Telo Genomics Announces Achieving Interim Results from Smouldering Myeloma Clinical Study

Telo Genomics Completes Processing of Multiple Myeloma Drug Resistance Patient Samples

Telo Genomics Launches Clinical Study of Drug Resistance Test for Multiple Myeloma

Telo Genomics Corp. Completes the Validation of Suite of Proprietary Automation Tools

Telo Genomics Launches Clinical Validation of its Smoldering Multiple Myeloma Diagnostic Test

Telo Genomics Corp. Appoints Ron McGlennen as Board of Director

Telo Genomics Corp. Advances Its Lead Product and Implements Automation to Its Workflow

Telo Genomics Corp. announced that it has received CAD 2.28775 million in funding

Telo Genomics Corp. announced that it expects to receive CAD 1.5 million in funding

Telo Genomics Appoints Gregg Mayer to Lead the Development of the Company’s Industry Partnership Strategy

Telo Genomics Corp., Annual General Meeting, Mar 04, 2021

Telo Genomics Corp. Announces the Positive Results of Its Smoldering Multiple Myeloma Proof of Concept Study

Telo Genomics Announces the Final Assignment of Patents on Hematological Cancers, Liquid Biopsy and Alzheimer’S Disease

Telo Genomics Corp. Announces That Positive Results of Smoldering Multiple Myeloma Study Selected for Online Publication Within Ash 2020 Proceedings

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin